Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Contribution of Immuno - PET préciblée the bispecific antibody with anti- CEA x anti -HSG peptide IMP and TF2 -288 labeled with Gallium -68 For Imaging of Patients Potentially Candidates An excisional surgery and / or thermoablation One or several of local metastases at diagnosis or relapse When Colo- rectal Cancers (CCR) Expressing Carcino antigen ( CEA) : Comparison with Conventional Review [Apport de l'Immuno-TEP préciblée Avec l'Anticorps bispécifique Anti-ACE x Anti-HSG TF2 et le Peptide IMP-288 marqué au Gallium-68 Pour l'Imagerie Des Patients Potentiellement Candidats à Une Chirurgie d'exérèse et/ou Thermoablation Locale d'Une ou Plusieurs métastases, au Diagnostic ou Lors de la Rechute de Cancers Colo-rectaux (CCR) Exprimant l'antigène Carcino-embryonnaire (ACE): Comparaison au Bilan Conventionnel]

Next Previous
Trial Profile

Contribution of Immuno - PET préciblée the bispecific antibody with anti- CEA x anti -HSG peptide IMP and TF2 -288 labeled with Gallium -68 For Imaging of Patients Potentially Candidates An excisional surgery and / or thermoablation One or several of local metastases at diagnosis or relapse When Colo- rectal Cancers (CCR) Expressing Carcino antigen ( CEA) : Comparison with Conventional Review [Apport de l'Immuno-TEP préciblée Avec l'Anticorps bispécifique Anti-ACE x Anti-HSG TF2 et le Peptide IMP-288 marqué au Gallium-68 Pour l'Imagerie Des Patients Potentiellement Candidats à Une Chirurgie d'exérèse et/ou Thermoablation Locale d'Une ou Plusieurs métastases, au Diagnostic ou Lors de la Rechute de Cancers Colo-rectaux (CCR) Exprimant l'antigène Carcino-embryonnaire (ACE): Comparaison au Bilan Conventionnel]

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 28 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gallium-68-IMP-288 (Primary) ; TF 2 (Primary)
  • Indications Colorectal cancer
  • Focus Diagnostic use
  • Acronyms iTEP Colon

    • Most Recent Events

    • 17 Jan 2017 Status changed from recruiting to completed.
    • 24 Mar 2016 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
    • 30 Oct 2015 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top